Literature DB >> 18220635

Metformin beyond diabetes: new life for an old drug.

Carlo M Rotella1, Matteo Monami, Edoardo Mannucci.   

Abstract

Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus. Although some caution is needed in the very old, advanced age per se does not represent a contraindication to metformin use. Despite the fact that its precise mechanism of action it is not completely elucidated, long-term treatment with this drug in monotherapy, improves glycaemic control and reduces cardiovascular mortality in overweight type 2 diabetic patients. Experimental evidence produced over the years suggests that metformin may be useful in some clinical conditions different from diabetes mellitus. In the present review we have examined currently available data about the possible use of metformin as an effective therapeutical agent in pathological conditions different from type 2 diabetes mellitus. On the basis of our investigation, the use of metformin can be suggested in overweigth patients affected by impaired glucose tolerance and/or fasting hyperglycaemia and in subjects affected by polycystic ovary syndrome, while further data are needed in order to prescribe such a drug in patients affected by non-alcoholic steato-hepatitis and in HIV patients on antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18220635     DOI: 10.2174/157339906777950651

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  17 in total

1.  Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.

Authors:  Manuel González-Ortiz; Esperanza Martínez-Abundis; José A Robles-Cervantes; Maria G Ramos-Zavala; Carmelita Barrera-Durán; Jorge González-Canudas
Journal:  Diabetes Technol Ther       Date:  2012-09-13       Impact factor: 6.118

2.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

3.  Orphan nuclear receptor small heterodimer partner negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of signal transducer and activator of transcription 5 (STAT5) transactivation.

Authors:  Yong Deuk Kim; Tiangang Li; Seung-Won Ahn; Don-Kyu Kim; Ji-Min Lee; Seung-Lark Hwang; Yong-Hoon Kim; Chul-Ho Lee; In-Kyu Lee; John Y L Chiang; Hueng-Sik Choi
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

Review 4.  Leptin revisited: its mechanism of action and potential for treating diabetes.

Authors:  Roberto Coppari; Christian Bjørbæk
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

5.  Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.

Authors:  Sunmi Park; Mark C Willingham; Jun Qi; Sheue-Yann Cheng
Journal:  Endocr Relat Cancer       Date:  2018-06-18       Impact factor: 5.678

Review 6.  Frontier of epilepsy research - mTOR signaling pathway.

Authors:  Chang Hoon Cho
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

7.  Effect of metformin on metabolic improvement and gut microbiota.

Authors:  Heetae Lee; GwangPyo Ko
Journal:  Appl Environ Microbiol       Date:  2014-07-18       Impact factor: 4.792

8.  Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice.

Authors:  Heetae Lee; Youngjoo Lee; Jiyeon Kim; Jinho An; Sungwon Lee; Hyunseok Kong; Youngcheon Song; Chong-Kil Lee; Kyungjae Kim
Journal:  Gut Microbes       Date:  2018-02-13

9.  Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats.

Authors:  Nilesh M Kalariya; Mohammad Shoeb; Naseem H Ansari; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-08       Impact factor: 4.799

10.  The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.

Authors:  Kathleen Hoeger; Kristen Davidson; Lynda Kochman; Tracy Cherry; Laurie Kopin; David S Guzick
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.